Abstract
Purpose To look at the incidence, symptomatology, course and reversibility of low-dose tamoxifen ocular toxicity.
Methods Sixty-five women with breast cancer, on tamoxifen oral therapy (20 mg/day), and a totally normal eye examination, were prospectively followed up. A full ophthalmic evaluation was done every 6 months, for a median of 30 months (range 4-79 months). Any sign of toxicity in the cornea, lens, retina or optic nerve was looked for, whether associated with a change in visual acuity or not.
Results Ocular toxicity was documented in 8 patients, giving an incidence of 12%. Seven patients had keratopathy in the form of subepithelial deposits, whorls and linear opacities. Three of these patients had a concurrent symptomatic bilateral pigmentary retinopathy that warranted discontinuation of therapy. One patient developed bilateral optic neuritis that left her with optic nerve pallor and a decrease in vision. The patients who had the toxicity had a significantly higher tamoxifen cumulative dose (p = 0.03), and were longer on treatment (p = 0.04), than the non-affected ones. The keratopathy changes were reversible upon discontinuation of the drug.
Conclusion Prompt reporting of symptoms and yearly ophthalmic examinations are mandatory in patients on tamoxifen to detect toxic effects while these are still reversible.
Similar content being viewed by others
Article PDF
References
Clark JH, Peck EJ Jr, Anderson JN . Oestrogen reception and antagonism of steroid hormone action. Nature 1974;251:446–8.
Imperia PS, Lazarus HM, Lass J . Ocular complications of systemic cancer chemotherapy. Surv Ophthalmol 1989;34:219–30.
Sananes S, Khairallah T, Touboul E, Salat-Baroux J, Uzan S . A surveillance of patients treated with tamoxifen. Presse Med 1996;25:499–502.
Seoud M, Johnson J, Weed JC . Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynaecol 1993;82:165–9.
Kaiser-Kupfer MI, Lippman ME . Tamoxifen retinopathy. Cancer Treat Rep 1978;62:315–20.
McKeown CA, Swart ZM, Bloom J, Maggiano JM . Tamoxifen retinopathy. Br J Ophthalmol 1981;65:177–9.
Gerner EW . Ocular toxicity of tamoxifen. Ann Ophthalmol 1989;21:420–3.
Bentley CR, Davies G, Aclimandos WA . Tamoxifen retinopathy: a rare but serious complication. BMJ 1992;304:495–6.
Vinding T, Nielsen NV . Retinopathy caused by treatment with tamoxifen in low dose. Acta Ophthalmol (Copenh) 1983;61:45–50.
Griffiths M . Tamoxifen retinopathy at low dosage. Am J Ophthalmol 1987;104:185–6.
Chang T, Gonder JR, Ventresco MR . Low-dose tamoxifen retinopathy. Can J Ophthalmol 1992;27:148–9.
Chern S, Danis R . Retinopathy associated with low-dose tamoxifen. Am J Ophthalmol 1993;116:372–3.
Pugesgaard T, Von Eyben FE . Bilateral optic neuritis evolved during tamoxifen treatment. Cancer 1986;58:383–6.
Ashford AR, Done VI, Tiwari RP, Garett TJ . Reversible ocular toxicity related to tamoxifen therapy. Cancer 1988;61:33–5.
Thersson R, Jansen E, Leys A, Rutten J, Meyskens J . Screening for tamoxifen ocular toxicity: a prospective study. Eur J Ophthalmol 1995;5:230–4.
Beck M, Mills PV . Ocular assessment of patients treated with tamoxifen. Cancer Treat Rep 1979;63:1833–4.
Longstaff S, Sigurdsson H, O'Keeffe M, Ogston S, Preece P . A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma. Eur J Cancer Clin Oncol 1989;25:1805–8.
Heier J, Dragoo R, Enzenauer R, Waterhouse W . Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Am J Ophthalmol 1994;117:772–5.
Palvidis NA, Petris C, Braissoulis, et al. Clear evidence that long-term, low dose tamoxifen treatment can induce ocular toxicity. Cancer 1992;69:2961–4.
Nayfield SG, Gorin MB . Tamoxifen-associated eye disease: a review. J Clin Oncol 1996;14:1018–26.
Schwartz PE, Keating G, MacLusky N . Tamoxifen therapy for advanced ovarian cancer. Obstet Gynecol 1982;59:583–8.
Crowson MC, Dorrel A, Rolfe EB, Fielding JWL . A phase II study to evaluate tamoxifen in pancreatic adenocarcinoma. Eur J Surg Oncol 1986;12:335–6.
Tonnesen K, Kamp-Jensen M . Antiestrogen therapy in pancreatic carcinoma: a preliminary report. Eur J Surg Oncol 1986;12:69–70.
Meyskens FL Jr, Voakes JB . Tamoxifen in metastatic malignant melanoma. Cancer Treat Rep 1980;64:171–3.
Kramer BS, Brawley OW, Nayfield S, et al. NCI studies in primary prevention of breast and prostatic cancer. Cancer Res Ther Control 1993;3:203–11.
Lullman H, Lullman-Rauch R, Wasserman O . Drug induced phospholipidoses. Crit Rev Toxicol 1975;4:185–218.
Kaiser-Kupfer MI, Kupfer C, Rodrigues MM . Tamoxifen retinopathy: a clinicopathologic report. Ophthalmology 1981;88:89–93.
Lullman H, Lullman-Rauch R . Tamoxifen induced generalized lipidosis in rats subchronically treated with high doses. Toxicol Appl Pharmacol 1981;61:138–46.
Drenckhahn D, Lullman-Rauch R . Drug induced retinal lipidosis: differential susceptibilities of pigment epithelium and neuroretina toward several amphilic cationic drugs. Exp Mol Pathol 1978;28:360–71.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Noureddin, B., Seoud, M., Bashshur, Z. et al. Ocular toxicity in low-dose tamoxifen: A prospective study. Eye 13, 729–733 (1999). https://doi.org/10.1038/eye.1999.217
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/eye.1999.217
Keywords
This article is cited by
-
Consequences of Antineoplastic Treatment on Visual Processing of Women with Breast Cancer: a Systematic Review
Trends in Psychology (2023)
-
Ocular Toxicity of Targeted Anticancer Agents
Drugs (2021)
-
The optic nerve head in acquired optic neuropathies
Nature Reviews Neurology (2010)
-
Ungewöhnliches Erscheinungsbild einer tamoxifenassoziierten Makulopathie
Der Ophthalmologe (2010)
-
Retinal function in patients treated with tamoxifen
Documenta Ophthalmologica (2010)